7:06 Timing Discontinuation of Treatment: Critical to Maximize Chances of Successful TFR November 5, 2022 • CML Content Hub @FadiHaddad_MD, of @MDAndersonNews, discusses #treatment #discontinuation in #CML.
:39 Additional Chromosomal Abnormalities in CML: An Indication for Close Monitoring November 3, 2022 • CML Content Hub Susanne Saussele, MD, discusses the importance of #chromosome #abnormalities in #CML.
:59 FLOT2 Deficiency and Prolonged Survival in CML November 2, 2022 • CML Content Hub Daniela Krause, MD, of @goetheuni, discusses #FLOT2 deficiency and #survival in #CML.
1:09 Selecting CML Patients Eligible for Treatment Cessation November 2, 2022 • CML Content Hub Susanne Saussele, MD, discusses #treatment #discontinuation in #CML.
1:02 Votobatinib Promising in Phase 1/2 Trial of Mostly Heavily Pretreated CML Patients November 1, 2022 • CML Content Hub @GCC_Cortes, of @GACancerCenter, discusses #votobatinib in #CML.
2:42 Managing Long-Term Toxicities in Pediatric CML-CP November 1, 2022 • CML Content Hub Nirmalya Roy Moulik, MD, PhD, of @TataMemorial, discusses #chronic #phase #CML in #pediatric patients.
55:37 Joseph Leiter Memorial Lecture: Emerging Infectious Diseases October 29, 2022 • Infectious Diseases @JonnaMazet discusses #emerging #infectiousdiseases in the 21st century.
1:21 Managing Challenging CML Cases October 29, 2022 • CML Content Hub Susanne Saussele, MD, discusses #monitoring after #treatment #discontinuation in #CML.
2:08 Mitochondrial Metabolism Inhibitors as a CML Treatment? October 28, 2022 • CML Content Hub @VignirHelgason, of @UofGlasgow, discusses #mitochondrial #metabolic #inhibitors for #CML.
1:41 Risk Stratifying CML Patients for Cardiovascular Adverse Events When Choosing First-Line Therapy October 27, 2022 • CML Content Hub @mjmauroMD, of @MSKCancerCenter, discusses #risk stratification and #TKI selection in #CML.
1:53 5-Year Results Solidify Bosutinib’s Increased Efficacy vs Imatinib October 23, 2022 • CML Content Hub @GCC_Cortes of @GACancerCenter discusses #bosutinib in #CML.
2:28 Optimizing CML Treatment: Latest Clinical Trial Data on TKI Efficacy and Dosage October 21, 2022 • CML Content Hub @CoplandMhairi, of @UofGlasgow, discusses #TKI efficacy and #dosage.
